Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$120.4 - $237.13 $2.06 Million - $4.05 Million
-17,074 Reduced 94.71%
953 $220,000
Q3 2023

Nov 13, 2023

BUY
$146.04 - $225.78 $2.63 Million - $4.07 Million
18,027 New
18,027 $2.63 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.37B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Center Book Partners LP Portfolio

Follow Center Book Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Center Book Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Center Book Partners LP with notifications on news.